Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences finite-lived intangible assets — Accumulated amortization ($M) ($M)
Form 10-Q / 10-K Note 9 Goodwill and Intangible Assets
Latest, Q2 2026
18,382
Period ended Jun 30, 2026
Change on a year earlier
+14.8%
16,019 in Q2 2025
History
50 quarters
Since Q1 2014
Sources
47
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-lived intangible assets — Accumulated amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 18,382 | +14.8% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 17,782 | +15.3% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 17,211 | +16.1% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 16,614 | +16.8% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 16,019 | +17.5% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 15,421 | +18.3% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 14,822 | +19.2% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 14,224 | +19.9% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 13,628 | +21.0% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 13,032 | +22.2% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 12,436 | +22.9% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 11,863 | +22.3% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 11,265 | +21.7% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 10,667 | +20.8% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 10,121 | +20.8% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 9,700 | +22.2% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 9,254 | +23.5% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 8,827 | +25.1% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 8,381 | +25.8% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 7,936 | +25.7% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 7,495 | +24.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 7,055 | +9.6% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 6,660 | +8.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2020 | Sep 30, 2020 | 6,312 | +7.4% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 6,031 | +7.8% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 6,437 | +21.3% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 6,156 | +22.9% | Form 10-Q (filed 2020-05-06) ↗ |
| Q3 2019 | Sep 30, 2019 | 5,875 | +24.8% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 5,594 | +27.0% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 5,306 | +29.3% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,007 | +31.6% | Form 10-Q (filed 2019-11-05) ↗ |
| Q3 2018 | Sep 30, 2018 | 4,706 | +33.7% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 4,405 | +33.0% | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 4,105 | +32.3% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 3,804 | +31.5% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 3,521 | +31.5% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 3,312 | +34.2% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 3,102 | +37.4% | Form 10-Q (filed 2017-05-10) ↗ |
| Q4 2016 | Dec 31, 2016 | 2,892 | +41.2% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 2,678 | +45.5% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 2,468 | +50.9% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 2,258 | +58.1% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 2,048 | +67.6% | Form 10-K (filed 2017-02-27) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,841 | +86.1% | Form 10-Q (filed 2015-11-04) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,635 | +107.6% | Form 10-Q (filed 2015-08-05) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,428 | +142.9% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 1,222 | – | Form 10-K (filed 2016-02-24) ↗ |
| Q3 2014 | Sep 30, 2014 | 989 | – | SEC Filing ↗ |
| Q2 2014 | Jun 30, 2014 | 788 | – | SEC Filing ↗ |
| Q1 2014 | Mar 31, 2014 | 588 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Finite-lived intangible assets — Accumulated amortization ($M) ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_finite_accum
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.